small molecule

CONTRAVE

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

Loss of exclusivityJuly 2034latest FDA-listed patent expiry

CompanyNalpropion Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	CONTRAVE
Active ingredient	BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE
Strength	90MG;8MG
Dosage form	TABLET, EXTENDED RELEASE
Route	ORAL
Modality	Small molecule
FDA approval	September 2014
Marketing status	RX

Listed patents

Patent	Expires	Type
10828294	July 2034	use U-1583
11998542	July 2034	use U-1583
10231964	July 2034	use U-1583
10835527	July 2034	use U-1583
9633575	June 2033	use U-1583
10403170	June 2033	use U-1583
11139056	June 2033	use U-1583
9248123	January 2032	use U-1808
11033543	January 2031	use U-1583
8916195	February 2030	use U-1639
11324741	May 2029	use U-1583
8088786	February 2029	product
12048769	November 2027	use U-1585
9125868	November 2027	use U-1585
10307376	November 2027	use U-1585
8722085	November 2027	use U-1585
8318788	November 2027	use U-1584
9107837	June 2027	use U-1639

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.